Lucinda Quan
Founder bij ALIGOS THERAPEUTICS, INC.
Vermogen: 377 109 $ op 31-03-2024
Profiel
Lucinda Y.
Quan is the founder of Aligos Therapeutics, Inc. which was founded in 2018.
She held the titles of Chief Business Officer, EVP & General Counsel.
Ms. Quan's former jobs include Executive Director-Business Development at Merck & Co., Inc. from 2016 to 2018, VP-Legal Affairs & Associate General Counsel at InterMune, Inc. from 2004 to 2013, and Vice President & Head-Legal Affairs at Alios BioPharma, Inc. from 2013 to 2016.
Ms. Quan received her undergraduate and graduate degrees from the University of California, Los Angeles.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-09-2023 | 384 805 ( 0.53% ) | 377 109 $ | 31-03-2024 |
Actieve functies van Lucinda Quan
| Bedrijven | Functie | Begin |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Founder | 05-02-2018 |
Eerdere bekende functies van Lucinda Quan
| Bedrijven | Functie | Einde |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01-04-2018 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | General Counsel | 01-01-2016 |
| INTERMUNE INC | General Counsel | 01-11-2013 |
Opleiding van Lucinda Quan
| University of California, Los Angeles | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
